Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that licenses drug technologies and collects royalties on medicines its partners develop and sell. Its best-known asset is Captisol, a sugar-based "cage" that wraps around hard-to-dissolve drugs to make them stable and deliverable. Founded in 1987 as Progenx, Inc., it was renamed Ligand Pharmaceuticals in 1989 after the biochemistry term for a molecule that binds to a receptor — a nod to its original focus on receptor biology.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -88.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.